Hyperlipidemia, tissue factor, coagulation, and simvastatin

被引:113
作者
Owens, Albert Phillip, III [1 ]
Byrnes, James Robert [1 ]
Mackman, Nigel [1 ]
机构
[1] Univ N Carolina, Div Hematol & Oncol, Dept Med, McAllister Heart Inst, Chapel Hill, NC 27599 USA
关键词
HUMAN ENDOTHELIAL-CELLS; TOLL-LIKE RECEPTOR-4; GENE-DELETED MICE; FACTOR EXPRESSION; SCAVENGER RECEPTORS; RANDOMIZED-TRIAL; RHO/RHO-KINASE; OXIDIZED LDL; IN-VIVO; MICROPARTICLES;
D O I
10.1016/j.tcm.2013.07.003
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
Hyperlipidemia affects millions of people worldwide and is a major risk factor for cardiovascular disease. People with hyperlipidemia have elevated levels of serum cholesterol and an increased risk of thrombosis. Studies have suggested that oxidized lipoproteins, such as oxidized low-density lipoprotein (oxLDL), contribute to the development of a pro-thrombotic state. In this review, we discuss our recent studies demonstrating a role for hematopoietic cell-derived tissue factor (TF) expression in the activation of coagulation and increased thrombosis associated with hyperlipidemia. In addition, we investigated the effect of simvastatin on TF expression and coagulation. We found that simvastatin reduced leukocyte TF expression, TF+ microparticles, and coagulation. These results and earlier studies suggest that the anti-coagulant activity of statins is due, in part, to their ability to reduce monocyte TF expression in patients with cardiovascular disease. (C) 2013 Elsevier Inc. All rights reserved.
引用
收藏
页码:95 / 98
页数:4
相关论文
共 45 条
[1]
Aikawa M, 2001, CIRCULATION, V103, P276
[2]
Effect of statin therapy on C-reactive protein levels - The Pravastatin Inflammation/CRP Evaluation (PRINCE): A randomized trial and cohort study [J].
Albert, MA ;
Danielson, E ;
Rifai, N ;
Ridker, PM .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 286 (01) :64-70
[3]
Simvastatin inhibits expression of tissue factor in advanced atherosclerotic lesions of apolipoprotein E deficient mice independently of lipid lowering: potential role of simvastatin-mediated inhibition of Egr-1 expression and activation [J].
Bea, F ;
Blessing, E ;
Shelley, MI ;
Shultz, JM ;
Rosenfeld, ME .
ATHEROSCLEROSIS, 2003, 167 (02) :187-194
[4]
Oxidized phlospholipids stimulate tissue factor expression in human endothelial cells via activation of ERK/EGR-1 and Ca++/NFAT [J].
Bochkov, VN ;
Mechtcheriakova, D ;
Lucerna, M ;
Huber, J ;
Malli, R ;
Graier, WF ;
Hofer, E ;
Binder, BR ;
Leitinger, N .
BLOOD, 2002, 99 (01) :199-206
[5]
Boullier A, 2001, ANN NY ACAD SCI, V947, P214
[6]
Pravastatin reduces thrombogenicity by mechanisms beyond plasma cholesterol lowering [J].
Casani, L ;
Sanchez-Gomez, S ;
Vilahur, G ;
Badimon, L .
THROMBOSIS AND HAEMOSTASIS, 2005, 94 (05) :1035-1041
[7]
Vastatins inhibit tissue factor in cultured human macrophages - A novel mechanism of protection against atherothrombosis [J].
Colli, S ;
Eligini, S ;
Lalli, M ;
Camera, M ;
Paoletti, R ;
Tremoli, E .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1997, 17 (02) :265-272
[8]
Native and oxidized low density lipoprotein induction of tissue factor gene expression in smooth muscle cells is mediated by both Egr-1 and Sp1 [J].
Cui, MZ ;
Penn, MS ;
Chisolm, GM .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (46) :32795-32802
[9]
Non lipid, dose-dependent effects of pravastatin treatment on hemostatic system and inflammatory response [J].
Di Garbo, V ;
Bono, M ;
Di Raimondo, D ;
De Simone, R ;
Raneli, G ;
Avellone, G .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2000, 56 (04) :277-284
[10]
Impaired fibrinolytic system in ApoE gene-deleted mice with hyperlipidemia augments deep vein thrombosis [J].
Diaz, Jose A. ;
Ballard-Lipka, Nicole E. ;
Farris, Diana M. ;
Hawley, Angela E. ;
Wrobleski, Shirley K. ;
Myers, Daniel D. ;
Henke, Peter K. ;
Lawrence, Daniel A. ;
Wakefield, Thomas W. .
JOURNAL OF VASCULAR SURGERY, 2012, 55 (03) :815-822